Deepa is an entrepreneur, biotech investor and a CEO. She is currently the CEO and founder of a biotech company operating in stealth mode. While a managing member and sole biotech partner at Delphi Ventures from 2001-2023, Deepa built the biotech practice and funded companies that developed eleven drugs that are on the market helping patients, including three that generate over $1 billion in revenue each. Prior to joining Delphi, from 1998-2001, Deepa was an M&A and corporate finance banker in the healthcare group at J.P. Morgan, and from 1997-1998 was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech from 1993 to 1997.

She serves on the board of Calithera Biosciences where she is lead director, as well as Karyopharm Therapeutics, Mereo BioPharma, Theravance Biopharma, Palleon Pharmaceuticals, and Freenome. She serves as Executive vice-chair on the San Francisco Conservatory of Music’s Board of Trustees.

Deepa received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.

Senior Advisors